2. Barlow WE, White E, Ballard-Barbash R et al. (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography. *J Natl Cancer Inst* 17: 1204–1214
3. Boyd NF, Martin LJ, Sun L et al. (2006) Body size, mammographic density, and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 15: 2086–2092
4. Duffy SW, Chen H (1996) Parameters of screening practice and outcome-variation among programmes (abstract) in, The impact of breast cancer screening with mammography in women aged 40–49 years, Falun Meeting, March 21–22
5. Duffy SW, Day NE, Tabár L et al. (1997) Markov models of breast tumor progression: Some age-specific results. *J Natl Cancer Inst Monogr* 22: 93–97
6. Duffy SW (2006) Reduction in breast cancer mortality from organized service screening with mammography: 1. Further Confirmation with extended Data. *Cancer Epidemiol Biomarkers Prev* 15: 45–51
7. Duffy SW (2006) Reduction in breast cancer mortality from organized service screening with mammography: 2. Validation with alternative analytic methods. *Cancer Epidemiol Biomarkers Prev* 15: 52–56
8. European Community (2006) European guidelines for quality assurance in mammography screening and diagnosis, 4th edn. Europe Against Cancer Programme, Luxembourg (http://www.ec.europa.eu/comm/health/ph_projects/2002/cancer/fp_cancer_2002_ext_guid_01.pdf)
9. Fracheboud J, Groenewoud JH, Boer R et al. (2005) Seventy-five years in an appropriate upper age limit for population-based mammography screening. *Int J Cancer* 188: 2020–2025
10. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg) (2006) Krebs in Deutschland. Häufigkeiten und Trends, 5. überarb. aktualisierte Ausgabe
11. Gohagen JK, Spitznagel EL, McGrath MM, Frank TB (1984) ROC analysis of mammography and palpation for breast screening. *Invest Radiol* 19: 587
12. Goldmann A, Phillips N, Warren L, Kan L (2006) Breast cancer mortality after screening mammography in British Columbia women. *Int J Cancer* 120: 1076–1080
13. Hendrick RE, Smith RA, Rudle JH, Smart CR (1997) Benefit of screening mammography in women aged 40–49; a new meta-analysis of randomized trials. *Mogr Natl Cancer Inst* 22: 87–92
14. Hofvind S, Wang H, Thoresen S (2004) Do the results of the process indicators in the Norwegian breast cancer screening program predict future mortality reduction from breast cancer? *Acta Oncol* 5: 467–473
15. Hofvind S, Möller B, Thoresen St, Ursin G (2006) Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. *Int J Cancer* 118: 3112–3117
16. Vainio H, Bianchini F (eds) (2002) Breast cancer screening – IARC Handbooks of cancer prevention, vol 7. IARC, Lyon, pp 157–170
17. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften (S3-Leitlinie) (Hrsg) (2004) Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau. Zuckschwert, München Wien New York
18. Katalinic A, Bartel C, Raspe H, Schreer I (2007) Beyond mammography screening: quality assurance in breast cancer diagnosis (The QuaMaDi Project). *Br J Cancer* 96: 157–161
19. Katalinic A, Hense H-W, Becker N (2006) Krebsregistrierung in Deutschland. *Onkologie* 12: 1084–1093
20. Kuhl C (2007) Stellungnahme der Deutschen Röntgengesellschaft (DRG) zum Mammographie-Screening. *Senologie* 1: V–IX
21. Larsson LG, Andersson I, Bjurström N et al. (1997) Updated overview of the Swedish randomized trials on breast cancer screening with mammography: age group 40–49 at randomization. *J Natl Cancer Inst Monogr* 22: 87–92
22. Nystrom L, Andersson I, Bjurström N et al. (2002) Long-term effects of mammography screening: updated overview of the Swedish randomised trials. *Lancet* 359: 909–919
23. Sarkeala T, Hakama M, Saarenmaa I et al. (2006) Episode sensitivity in association with process indicators in the Finnish breast cancer screening program. *Int J Cancer* 188: 174–179
24. Schreer I (2001) Auswertung der bisherigen Mammographie-Screening-Studien in Europa und in Nordamerika. *Radiologe* 41: 344–351
25. Schreer I (2002) Mammographiescreening – sekundäre Prävention. *Gynäkologe* 35: 533–560
26. Schreer I, Katalinic A (2006) Mammographie-Screening und Brustkrebsfrüherkennung. *Gynäkologe* 39: 503–508
27. Schreer I, Katalinic A (2007) Is high quality breast imaging and diagnosis possible in a decentralized system? The QuaMaDi project. *Breast Care* 2: 20–24
28. Smith RA (2000) Breast cancer screening among women younger than age 50: A current assessment of the issues. *CA Cancer J Clin* 50: 312–336
29. Tabár L, Chen HH, Frøberg G et al. (1997) Recent results from the Swedish Two-Country Trial: The effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. *J Natl Cancer Inst Monogr* 22: 43–47
30. Tabár L, Dean PB (2003) Mammography and breast cancer: the new era. *Int J Gynecol Obstet* 82: 319–326

Gynäkologe 2007 · 40:418
DOI 10.1007/s00129-007-2007-6
Online publiziert: 23. Mai 2007
© Springer Medizin Verlag 2007

R. Freynhagen D.E.A.A. · A. Schmitz ·
P. Busche · U. Junker

Schmerztherapie und Symptomkontrolle in der Palliativmedizin

Gynäkologe (2007) 40:168–177

Im oben genannten Beitrag wurden in
Tabelle 3 versehentlich falsche Dosangaben
gemacht. Richtig muss es heißen:

Gabapentin: 300 mg/Tag, bis 3600 mg/Tag
Pregabalin: 75 mg/Tag, bis 600 mg/Tag

Wir bitten um Beachtung.